FrancophonIA/ELRC3.0 huggingface dataset:
English: For PBPC mobilisation in normal donors, filgrastim should be administered at 1.0 MIU (10 μg)/kg/day for 4 to 5 consecutive days.
Estonian: Tervetele doonoritele manustatakse vereloome tüvirakkude perifeersesse verre mobiliseerimiseks filgrastiimi 4...5 järjestikusel päeval annuses 1,0 MIU (10 μg)/kg ööpäevas.
English: There is insufficient data to evaluate filgrastim use in geriatric subjects for other approved filgrastim indications.
Estonian: Filgrastiimi kasutamise hindamiseks eakatel teiste kinnitatud näidustuse korral ei ole piisavalt andmeid.
English: Special precautions in patients undergoing PBPC mobilisation Mobilisation
Estonian: Erilised ettevaatusabinõud patsientidel, kellel mobiliseeritakse perifeerse vere vereloome tüvirakke
English: Vascular disorders, including veno-occlusive disease and fluid volume disturbances, have been reported occasionally in patients undergoing high dose chemotherapy followed by transplantation.
Estonian: Patsientidel, kes said suurtes annustes kemoteraapiat, millele järgnes siirdamine, on aeg-ajalt teatatud vaskulaarsetest häiretest, sealhulgas oklusiivsed veenihaigused ning vedeliku tasakaaluhäired.
English: Blood glucose decreased Pseudogouta
Estonian: Glükoosisisalduse vähenemine veres
English: Patients with renal or hepatic impairment
Estonian: Raskekujulise kroonilise neutropeeniaga patsiendid
English: Marketing Authorisation Holder ratiopharm GmbH Graf-Arco-Straße 3 89079 Ulm Germany
Estonian: Müügiloa hoidja ratiopharm GmbH Graf-Arco-Straße 3 89079 Ulm Saksamaa
English: The recommended dose of filgrastim for PBPC mobilisation when used alone is 1.0 MIU (10 μg)/kg/day for 5 to 7 consecutive days.
Estonian: Vereloome tüvirakkude mobiliseerimisel perifeersesse verre on filgrastiimi soovitatav annus monoteraapiana 1,0 MIU (10 μg)/kg ööpäevas 5...7 järjestikuse päeva jooksul.
English: Blood alkaline phosphatase increased
Estonian: Hepatomegaalia Alkaalse fosfataasi aktiivsuse suurenemine veres
English: Each mL of solution for injection/infusion contains 60 million international units [MIU] (600 microgram) of filgrastim.
Estonian: - Toimeaine on filgrastiim.Iga ml süste-/infusioonilahust sisaldab 60 miljonit rahvusvahelist ühikut [MIU] (600 mikrogrammi) filgrastiimi.
English: Special precautions in normal donors undergoing PBPC mobilisation
Estonian: Erilised ettevaatusabinõud perifeerse vere vereloome tüvirakkude mobiliseerimisel tervetel doonoritel
English: Ratiograstim 48 MIU/0.8 mL solution for injection/infusion Filgrastim
Estonian: Ratiograstim 48/0,8 ml MIU süste-/infusioonilahus Filgrastiim
English: Insomnia
Estonian: Hingamispuudu
English: Metabolis m and nutrition disorders
Estonian: Ainevahetus- ja toitumishäired
English: Ratiograstim contains sodium
Estonian: Ratiograstim sisaldab naatriumi
English: Uncommon (may affect up to 1 in 100 people):
Estonian: Aeg-ajalt (võib esineda kuni ühel inimesel 100st):
English: Ratiograstim 48 MIU/0.8 mL solution for injection/ infusion Filgrastim
Estonian: Ratiograstim 48 MIU/0,8 ml süste-/infusioonilahus Filgrastiim
English: You should talk to your doctor about your risks of developing cancers of the blood and what testing should be done.
Estonian: Te peate verevähi tekke ning vajalike analüüside osas pidama nõu oma arstiga.
English: The safety and efficacy of filgrastim administration in patients with myelodysplastic syndrome or chronic myelogenous leukaemia have not been established.
Estonian: Müelodüsplastilise sündroomi või kroonilise müeloidleukeemiaga patsientidel ei ole filgrastiimi kasutamise ohutust ja efektiivsust tõestatud.
English: Filgrastim may be given as a 24 hour subcutaneous continuous infusion or subcutaneous injection.
Estonian: Filgrastiimi monoteraapia kasutamine perifeerse vere vereloome tüvirakkude mobiliseerimiseks Filgrastiimi võib manustada pideva, 24 tundi kestva subkutaanse infusioonina või subkutaanse süstena.
English: Consideration should be given to temporary discontinuation or dose reduction of filgrastim in patients with severe chronic neutropenia who develop thrombocytopenia (platelet count < 100 x 109/l).
Estonian: Raske kroonilise neutropeeniaga patsientidel, kellel tekib trombotsütopeenia (trombotsüütide arv on < 100 x 109/l), peab kaaluma filgrastiimi manustamise ajutist katkestamist või annuse vähendamist.
English: Geriatric Use
Estonian: Manustamisviis
English: Infestations
Estonian: Peavalua
English: Talk to your doctor, pharmacist or nurse before using Ratiograstim.
Estonian: Enne Ratiograstim´i kasutamist pidage nõu oma arsti, apteekri või meditsiiniõega.
English: Paraesthesia
Estonian: Annustamine
English: Contents of the pack and other information
Estonian: Pakendi infoleht: teave kasutajale
English: Rare to
Estonian: Halb enesetunnee
English: Lung infiltrationa
Estonian: Pseudopodagraa
English: Sickle cell crisis, in some cases fatal, have been reported with the use of filgrastim in patients with sickle cell trait or sickle cell disease.
Estonian: Filgrastiimi kasutamisel sirprakulise aneemia kandlusega ja sirprakulise aneemiaga patsientide raviks on teatatud sirprakuliste kriiside tekkest, mis mõnel juhul lõppesid surmaga.
English: Gastrointestinal disorders
Estonian: Kõrvalekalded uriinianalüüsi näitudes
English: • dizziness
Estonian: • kopsuverejooks
English: • low red blood cell count (anaemia)
Estonian: • punavereliblede väike arv (aneemia)
English: In patients with severe chronic neutropenia (SCN) Posology
Estonian: Raske kroonilise neutropeeniaga lapsed
English: Astheniaa Malaisee Oedema peripherale
Estonian: Perifeerne tursee
English: Fluid volume disturbances
Estonian: Seedetrakti häired
English: To give yourself a subcutaneous injection you will need: - a pre-filled syringe of Ratiograstim; - alcohol wipes or similar.
Estonian: Endale nahaaluse süste tegemiseks vajate te: - Ratiograstim´i süstel,
English: Injection site reaction
Estonian: Anafülaktiline reaktsioon
English: Cutaneous vasculitisa
Estonian: Naha vaskuliita
English: Graft versus Host
Estonian: Alopeetsiaa Löövea Erüteem
English: Because of the potential of receiving higher doses of chemotherapy (e.g., full doses on the prescribed schedule) the patient may be at greater risk of thrombocytopenia and anaemia.
Estonian: Patsiendil võib olla suurem trombotsütopeenia ja aneemia tekkerisk, kuna võimalikud määratavad kemoteraapia annused on suuremad (nt määratud raviskeemi täisannused).
English: b.Tabulated summary of adverse reactions
Estonian: c. Valitud kõrvaltoimete kirjeldus
English: Special precautions in recipients of allogeneic PBPCs mobilised with filgrastim
Estonian: Erilised ettevaatusabinõud filgrastiimiga mobiliseeritud allogeensete perifeersest verest isoleeritud vereloome tüvirakkude retsipientide puhul
English: Headachea
Estonian: Iiveldusa
English: Cases of decreased bone density and osteoporosis have been reported in paediatric patients with SCN receiving chronic treatment with filgrastim.
Estonian: Filgrastiimiga pikaajaliselt ravitavatel raske kroonilise neutropeeniaga lastel on teatatud luutiheduse vähenemise ja osteoporoosi juhtudest.
English: Particular attention should be paid to the number of progenitors mobilised in such patients before the administration of high-dose chemotherapy.
Estonian: Enne suureannuselise kemoteraapia kasutamist on oluline hinnata mobiliseeritud tüvirakkude hulka.
English: 1 pre-filled syringe containing 0.8 mL 1 pre-filled syringe with safety device containing 0.8 mL 5 pre-filled syringes containing 0.8 mL 5 pre-filled syringes with safety device containing 0.8 mL 10 pre-filled syringes containing 0.8 mL
Estonian: 5 süstlit 0,8 ml, kaitseseadisega 10 süstlit 0,8 ml
English: Paina
Estonian: Valua
English: Belgium on 14/11/2006.
Estonian: Belgium 14/11/2006.
English: Page 2/2©EMEA 2006
Estonian: Lehekülg 2/2©EMEA 2006
English: It is available in three pack sizes; 55 ml or 120 ml bottles for dogs weighing up to 36 kg and a 210 ml bottle for dogs weighing up to 48 kg.
Estonian: Seda müüakse kolme eri suurusega pakendis: 55 ml või 120 ml pudel kuni 36 kg kaaluvatele koertele ning 210 ml pudel kuni 48 kg kaaluvatele koertele.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Yarvitan to Janssen Animal Health B.V.B.A.
Estonian: Euroopa Komisjon väljastas Yarvitani müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Janssen Animal Health B.V.B.A.
English: This veterinary medicine has been developed especially for dogs and is not for use in humans.
Estonian: See veterinaarravim on välja töötatud spetsiaalselt koertele ja see ei ole ette nähtud kasutamiseks inimestele.
English: Two large field trials were conducted, one in Europe and one in the USA, in healthy dogs which had a bodyweight 20% higher than recommended.
Estonian: Viidi läbi kaks suurt väliuuringut, üks Euroopas ja teine USAs, tervete koertega, kelle kehakaal oli 20% võrra soovitavast tasemest kõrgem.
English: This is related to the mode of action of the product.
Estonian: See on seotud ravimi toimimisviisiga.
English: The dogs also received other medicines during the study as required, such as vaccines, worming tablets, anti-flea or anti-tick treatments, antibiotics and anti-inflammatory medicines.
Estonian: Koerad said uuringus vajaduse korral ka muid ravimeid, näiteks vaktsiine, ussitõrjetablette, kirbu- ja puugitõrjeravimeid, antibiootikume ja põletikuvastaseid ravimeid.
English: In most cases, these effects are mild and stop without any treatment.
Estonian: Enamikul juhtudel on need kõrvaltoimed kerged ja kaovad ilma ravita.
English: The weight lowering effect was relatively moderate (in the range of 6-7 % of the weight before treatment).
Estonian: Kehakaalu alandav toime oli suhteliselt mõõdukas (6-7 % ravieelsest kaalust).
English: A reduced appetite may also occur during treatment.
Estonian: Ravi ajal võib ka isu väheneda.
English: Information on the prescription status of this product may be found on the label/outer package.
Estonian: Teave näidustuste kohta selle toote kasutamiseks on esitatud etiketil/välispakendil.
English: The treatment is an initial measure in an obesity management programme; it has to be combined with changes in diet, which must be continued after treatment is finished.
Estonian: Ravi on rasvumise vähendamise programmi esimene meede, millega peab kaasnema muudetud dieet, mida tuleb pärast ravi lõppu jätkata.
English: Yarvitan also has a slight appetite decreasing effect due to its mode of action.
Estonian: Yarvitanil on oma toimimisviisi tõttu ka kergelt isu vähendav toime.
English: About three-quarters received Yarvitan while the remainder received the medicine with the active substance removed (control group).
Estonian: Ligikaudu kolmveerand koertest said Yarvitani ja ülejäänud said ravimit, millest oli toimeaine eemaldatud (kontrollrühm).
English: It is used as part of a programme that also includes controlling the dog's intake of food.
Estonian: Seda kasutatakse programmi raames, mis hõlmab ka koera toitumise piiramist.
English: The medicine is administered to the dog for 3 weeks, followed by a 2-week medicine-free interval, when the veterinarian will adjust the dog's feeding according to its energy requirements.
Estonian: Ravimit antakse koerale kolme nädala jooksul, millele järgneb kahenädalane ravimivaba periood, mille jooksul loomaarst korrigeerib koera toitumist vastavalt tema energiavajadusele.
English: If a person accidentally takes the medicine, seek medical advice immediately and show the package leaflet or the label to a doctor.
Estonian: Juhusliku allaneelamise korral pöörduda kohe arsti poole ja näidata ravimi pakendi infolehte või etiketti.
English: This summary was last updated in September 2006.
Estonian: Kokkuvõtte viimane uuendus: 09-2006.
English: The dog then receives the medicine for a further 3 weeks, at the same time as the adjusted diet.
Estonian: Koer saab seejärel ravi veel kolme nädala jooksul, samaaegselt korrigeeritud dieediga.
English: Yarvitan has been studied in dogs in both laboratory and field trials.
Estonian: Yarvitani uuriti koertel nii laboratooriumi- kui väliuuringutes.
English: If accidental eye contact occurs, flush immediately with lots of water.
Estonian: Juhuslikul silmasattumisel tuleb silmi kohe rohke veega loputada.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Yarvitan exceed its risks for the management of overweight and obesity in dogs and recommended that Yarvitan be given a marketing authorisation.
Estonian: Veterinaarravimite komitee otsustas, et Yarvitani kasulikkus koerte ülekaalu ja rasvumise raviks on suurem kui sellega kaasnevad ohud, ning Yarvitanile soovitati anda müügiluba.
English: The active substance in Yarvitan, mitratapide, works in the gut by blocking a protein (the microsomal triglyceride transfer protein).
Estonian: Yarvitani toimeaine mitratapiid toimib sooltes teatud valgu (mikrosomaalse triglütseriidide transportvalgu) blokeerimise teel.
English: The dose to use is calculated according to the weight of the dog and the Yarvitan solution is given with the animal's food.
Estonian: Kasutatav annus arvutatakse koera kaalu järgi ning Yarvitani lahust antakse koerale koos toiduga.
English: Yarvitan at the recommended dose and using the 3-2-3 week treatment schedule reduced body weight in obese dogs when compared to the control group.
Estonian: Yarvitani kasutamisel soovitatud annuses, kasutades 3-2-3-nädalast raviskeemi, rasvunud koerte kehakaal võrreldes kontrollrühmaga vähenes.
English: Yarvitan contains the active substance mitratapide which helps to reduce weight in dogs.
Estonian: Yarvitan sisaldab toimeainena mitratapiidi, mis aitab koertel kaalus alla võtta.
English: Yarvitan is used in adult dogs that are overweight or obese, to help them lose weight.
Estonian: Yarvitani kasutatakse ülekaalulistel või rasvunud täiskasvanud koertel, et aidata neil kaalus alla võtta.
English: Vomiting, diarrhoea or softened faeces may occur during treatment.
Estonian: Ravi ajal võib esineda oksendamist, kõhulahtisust või pehmet väljaheidet.
English: What is the risk associated with Yarvitan?
Estonian: Millised on Yarvitaniga kaasnevad riskid?
English: What is Yarvitan?
Estonian: Mis on Yarvitan?
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) YARVITAN EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE YARVITAN Kokkuvõte üldsusele
English: For a full list of all side-effects reported with Yarvitan, see the Package Leaflet.
Estonian: Yarvitani kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: Why has Yarvitan been approved?
Estonian: Miks Yarvitan heaks kiideti?
English: Other information about Yarvitan:
Estonian: Muu teave Yarvitani kohta
English: How does Yarvitan work?
Estonian: Kuidas Yarvitan toimib?
English: How has Yarvitan been studied?
Estonian: Kuidas Yarvitani uuriti?
English: This protein is normally involved in the absorption of fats from the diet. By blocking the protein Yarvitan decreases the absorption of fats from the gut.
Estonian: Selle valgu blokeerimisega vähendab Yarvitan rasvade imendumist sooltest.
English: What is Yarvitan used for?
Estonian: Milleks Yarvitani kasutatakse?
English: Yarvitan is an oral solution, colourless to slightly yellow in colour.
Estonian: Yarvitan on värvitu või kollaka värvusega suukaudne lahus.
English: What benefit has Yarvitan shown during the studies?
Estonian: Milles seisneb uuringute põhjal Yarvitani kasulikkus?
English: Bottle (HDPE) 225 ml
Estonian: Pudel (HDPE) 225 ml
English: 1 bottle + 10 ml dosing syringe
Estonian: 1 pudel + 10 ml annustamissüstal
English: 50 mg/ml Oral suspension
Estonian: 50 mg/ml
English: 700 mg Film-coated tablets
Estonian: Õhukese polümeerikilega kaetud tablett
English: Invented name Strength Pharmaceutical form Route of administration Packaging Content
Estonian: Manustamisviis Pakend
English: Pharmaceutical Form Route of Administration Packaging Package size l t o r
Estonian: Tugevus Ravimvorm Manustamistee Pakendi iseloomustus Pakendi suurus l n a
English: (Invented) name Strength
Estonian: Ravimi (väljamõeld ud) nimetus
English: EMEA Number
Estonian: Müügiloa nr Euroopa Liidus
English: --1 Influenza A/eq/Ohio/03 [H3N8] recombinant canarypox virus (vCP2242) ≥ 5.3 log10 FAID50*/ml Influenza A/eq/Richmond/1/07 [H3N8] recombinant canarypox virus (vCP3011) ≥ 5.3 log10 FAID50*/ml * vCP content checked by global FAID50 (fluorescent assay infectious dose 50%) and qPCR ratio between vCP.
Estonian: --1 Influenza A/eq/Ohio/03 [H3N8] rekombinantne canarypox viirus (vCP2242) ≥ 5,3 log10 FAID50*/ml Influenza A/eq/ Newmarket/2/93 [H3N8] rekombinantne canarypox viirus (vCP1533) ≥ 5.3 log10 FAID50*/ml
English: Packaging Content Package Size
Estonian: Manustamisviis Pakend Sisaldus Pakendi suurus
English: Horses Intramuscular use Vial (glass) 1 ml
Estonian: Süstesuspensioon Hobused Intramuskulaarselt Viaal (klaas)
English: 10 vials Zero days
Estonian: 10 viaali
English: EU (MA) Number Invented name
Estonian: EL (MH) number Nimetus Tugevus Ravimvorm Loomaliigid
English: Fulphila (pegfilgrastim)
Estonian: Fulphila (pegfilgrastiim)
English: Filgrastim has been available in other medicines in the European Union (EU) for a number of years.
Estonian: Filgrastiimi on Euroopa Liidus muudes ravimites turustatud aastaid.
English: Further information on Fulphila can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/fulphila.
Estonian: Lisateave Fulphila kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/fulphila.
English: Neutropenia lasted 1 day on average with both medicines.
Estonian: Mõlema ravimiga kestis neutropeenia keskmiselt 1 päev.
English: What measures are being taken to ensure the safe and effective use of Fulphila?
Estonian: Mis meetmed võetakse, et tagada Fulphila ohutu ja efektiivne kasutamine?
English: Other information about Fulphila
Estonian: Muu teave Fulphila kohta
English: Patients can inject themselves if they have been trained appropriately.
Estonian: Kui patsiendid on saanud asjakohase väljaõppe, tohivad nad süstida ennast ise.
English: This means that Fulphila is highly similar to another biological medicine (the ‘reference medicine') that is already authorised in the EU.
Estonian: See tähendab, et Fulphila on väga sarnane teise bioloogilise ravimiga (võrdlusravimiga), millel juba on ELis müügiluba.
English: This slows down the removal of filgrastim from the body, allowing the medicine to be given less often.
Estonian: See aeglustab filgrastiimi väljutamist organimist, võimaldades harvemat manustamist.
English: Side effects reported with Fulphila are carefully evaluated and any necessary action taken to protect patients.
Estonian: Fulphila kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: As for all medicines, data on the use of Fulphila are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Fulphila kasutamise kohta pidevat järelevalvet.
English: The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Fulphila has a highly similar structure, purity and biological activity to Neulasta and is distributed in the body in the same way.
Estonian: Euroopa Ravimiamet otsustas, et vastavalt ELi nõuetele bioloogiliselt sarnaste ravimite kohta on Fulphila struktuuri, puhtuse ja bioloogilise toime poolest väga sarnane Neulastaga ning jaotub organismis samamoodi.
English: It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (when neutropenia is accompanied by fever).
Estonian: Seda kasutatakse eelkõige neutropeenia kestuse vähendamiseks ja febriilse neutropeenia (neutropeenia koos palavikuga) ennetamiseks.
English: What is Fulphila and what is it used for?
Estonian: Mis on Fulphila ja milleks seda kasutatakse?
English: For more information about using Fulphila, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Fulphila kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Therefore, the Agency's view was that, as for Neulasta, the benefit of Fulphila outweighs the identified risk and it can be authorised for use in the EU.
Estonian: Seetõttu on amet arvamusel, et nagu ka Neulasta korral, ületab Fulphila kasulikkus sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: The most common side effect with Fulphila (which may affect more than 1 in 10 people) is pain in the bones.
Estonian: Fulphila kõige sagedam kõrvalnäht (võib esineda enam kui 1 patsiendil 10st) on luuvalu.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Fulphila have been included in the summary of product characteristics and the package leaflet.
Estonian: Fulphila ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The active substance in Fulphila, pegfilgrastim, is a form of filgrastim, which is very similar to a human protein called granulocyte-colony-stimulating factor (G-CSF).
Estonian: Fulphila toimeaine pegfilgrastiim on filgrastiimi vorm, mis on väga sarnane teatud inimvalgugagranulotsüütide kolooniaid stimuleeriva faktoriga (G-CSF).
English: The safety of Fulphila has been evaluated, and on the basis of all the studies carried out the side effects of the medicine are considered to be comparable to those of the reference medicine Neulasta.
Estonian: Fulphila ohutust on hinnatud ja kõigi uuringute põhjal peetakse ravimi kõrvalnähte võrreldavaks võrdlusravimi Neulasta kõrvlanähtudega.
English: Fulphila is given as a single dose of 6 mg injected under the skin at least 24 hours after the end of each cycle of chemotherapy (treatment with cancer medicines).
Estonian: Fulphilat manustatakse annuses 6 mg ühekordse subkutaanse süstena vähemalt 24 tundi pärast iga keemiaravitsükli (vähi ravimravi) lõppu.
English: Because Fulphila is a biosimilar medicine, the studies on effectiveness and safety of pegfilgrastim carried out with Neulasta do not all need to be repeated for Fulphila.
Estonian: Et Fulphila on bioloogiliselt sarnane ravim, ei pea Neulastaga tehtud pegfilgrastiimi efektiivsus- ja ohutusuuringuid Fulphilaga kordama.
English: The reference medicine for Fulphila is Neulasta.
Estonian: Fulphila võrdlusravim on Neulasta.
English: What are the risks associated with Fulphila?
Estonian: Mis riskid Fulphilaga kaasnevad?
English: Fulphila is not intended for use in patients with the blood cancer chronic myeloid leukaemia or with myelodysplastic syndromes (conditions in which large numbers of abnormal blood cells are produced, which can develop into leukaemia).
Estonian: Fulphila ei ole ette nähtud patsientidele, kellel on krooniline müeloidleukeemia (teatud verevähk) või müelodüsplastilised sündroomid (haigusseisundid, mille korral tekib patsiendi organismis palju ebanormaalseid vererakke, mille tagajärjel võib välja kujuneda leukeemia).
English: How is Fulphila used?
Estonian: Kuidas Fulphilat kasutatakse?
English: How does Fulphila work?
Estonian: Kuidas Fulphila toimib?
English: Laboratory studies comparing Fulphila with Neulasta have shown that the active substance in Fulphila is highly similar to that in Neulasta in terms of structure, purity and biological activity.
Estonian: Fulphilat võrreldi Neulastaga laboriuuringutes, mis tõendasid, et Fulphila toimeaine on struktuuri, puhtuse ja bioloogilise toime poolest väga sarnane Neulasta toimeainega.
English: For the full list of side effects and restrictions with Fulphila, see the package leaflet.
Estonian: Fulphila kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Studies have also shown that giving Fulphila produces similar levels of the active substance in the body to giving Neulasta.
Estonian: Uuringud on samuti tõendanud, et Fulphila tekitab organismis sarnase toimeainesisalduse kui Neulasta.